{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:56:56Z","timestamp":1793390216230,"version":"4.5.0"},"reference-count":34,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-1476_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Neurofilament light chain (NfL) is a biomarker of neuroaxonal damage in various neurological conditions, including multiple sclerosis (MS). With new analytical platforms entering the market, standardization of serum NfL (sNfL) measurement is essential. This study compared sNfL levels across three assays\u00a0\u2013\u00a0NF-light Advantage V2\/Plus (Quanterix), Lumipulse G NfL blood (FujiRebio), and Elecsys NfL (Roche Diagnostics)\u00a0\u2013\u00a0and derived conversion formulas for harmonization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1476_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum samples from three cohorts including healthy donors (n=303) and MS patients (n=181) were analyzed across three platforms. Passing-Bablok regression and correlation analyses assessed inter-platform agreement and potential systematic differences. Assays were further evaluated for their ability to detect MS disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1476_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All platforms showed strong correlations (Pearson&gt;0.98; Spearman&gt;0.90, p&lt;0.001). Absolute values from Elecsys were \u223c6-fold lower than the other assays. Fourteen of 484 samples (2.90\u202f%) showed substantial, retest-stable deviations (&gt;4 SD) on at least one platform. After excluding outliers, conversion formulas were derived to transform the values to the NF-light Advantage V2\/Plus scale: NfL=6.31 \u00d7 [Elecsys NfL] + 2.33\u202fng\/L; NfL=0.94\u00a0\u00d7\u00a0[Lumipulse G NfL] + 1.30\u202fng\/L. In MS patients, all platforms detected significant differences between relapse and remission (p&lt;0.001). Age-adjusted Z scores from converted values yielded the highest effect sizes (Cohen\u2019s d: 0.84 for NF-light Advantage, 1.11 for Elecsys, 0.93 for Lumipulse).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1476_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The three platforms demonstrated high correlation and comparable performance in sNfL quantification. About 3\u202f% of samples showed strong deviations, highlighting the need for vigilance and further harmonization. Age-adjusted Z scores may enhance clinical and research utility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-1476","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:59:16Z","timestamp":1765990756000},"page":"880-888","source":"Crossref","is-referenced-by-count":10,"title":["Comparative analysis of three platforms for serum NfL quantification in healthy controls and MS patients"],"prefix":"10.1515","volume":"64","author":[{"given":"Justina","family":"Dargvainiene","sequence":"first","affiliation":[{"name":"Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Campus Kiel and L\u00fcbeck , Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Torge","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Campus Kiel and L\u00fcbeck , Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Peter","family":"Wandinger","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Campus Kiel and L\u00fcbeck , Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Junker","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Campus Kiel and L\u00fcbeck , Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Markewitz","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Campus Kiel and L\u00fcbeck , Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Benkert","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Neurology, Departments of Biomedicine and Clinical Research , University Hospital and University of Basel , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Willemse","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Neurology, Departments of Biomedicine and Clinical Research , University Hospital and University of Basel , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Maleska","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Neurology, Departments of Biomedicine and Clinical Research , University Hospital and University of Basel , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven Ole","family":"Schuster","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine, University Hospital Schleswig-Holstein, Campus Kiel and L\u00fcbeck , Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Ziemann","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine, University Hospital Schleswig-Holstein, Campus Kiel and L\u00fcbeck , Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cansu","family":"Tafrali","sequence":"additional","affiliation":[{"name":"Department of Neurology , Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Martinez-Serrat","sequence":"additional","affiliation":[{"name":"Department of Neurology , Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Khalil","sequence":"additional","affiliation":[{"name":"Department of Neurology , Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Neurology, Departments of Biomedicine and Clinical Research , University Hospital and University of Basel , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Leypoldt","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Campus Kiel and L\u00fcbeck , Kiel , Germany"},{"name":"Department of Neurology , University Hospital Schleswig-Holstein, Campus Kiel , Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2026051215045265922_j_cclm-2025-1476_ref_001","doi-asserted-by":"crossref","unstructured":"Rissin, DM, Kan, CW, Campbell, TG, Howes, SC, Fournier, DR, Song, L, et al.. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010;28:595\u20139. https:\/\/doi.org\/10.1038\/nbt.1641.","DOI":"10.1038\/nbt.1641"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_002","doi-asserted-by":"crossref","unstructured":"Gaetani, L, Blennow, K, Calabresi, P, Di Filippo, M, Parnetti, L, Zetterberg, H. Neurofilament light chain as a biomarker in neurological disorders. J\u00a0Neurol Neurosurg Psychiatry 2019;90:870\u201381. https:\/\/doi.org\/10.1136\/jnnp-2018-320106.","DOI":"10.1136\/jnnp-2018-320106"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_003","doi-asserted-by":"crossref","unstructured":"Khalil, M, Teunissen, CE, Otto, M, Piehl, F, Sormani, MP, Gattringer, T, et al.. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577\u201389. https:\/\/doi.org\/10.1038\/s41582-018-0058-z.","DOI":"10.1038\/s41582-018-0058-z"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_004","doi-asserted-by":"crossref","unstructured":"Khalil, M, Teunissen, CE, Lehmann, S, Otto, M, Piehl, F, Ziemssen, T, et al.. Neurofilaments as biomarkers in neurological disorders \u2014\u00a0towards clinical application. Nat Rev Neurol 2024;20:269\u201387. https:\/\/doi.org\/10.1038\/s41582-024-00955-x.","DOI":"10.1038\/s41582-024-00955-x"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_005","doi-asserted-by":"crossref","unstructured":"Freedman, MS, Gnanapavan, S, Booth, RA, Calabresi, PA, Khalil, M, Kuhle, J, et al.. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine 2024;101:104970. https:\/\/doi.org\/10.1016\/j.ebiom.2024.104970.","DOI":"10.1016\/j.ebiom.2024.104970"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_006","doi-asserted-by":"crossref","unstructured":"Khalil, M, Pirpamer, L, Hofer, E, Voortman, MM, Barro, C, Leppert, D, et al.. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun 2020;11:812. https:\/\/doi.org\/10.1038\/s41467-020-14612-6.","DOI":"10.1038\/s41467-020-14612-6"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_007","doi-asserted-by":"crossref","unstructured":"Benkert, P, Meier, S, Schaedelin, S, Manouchehrinia, A, Yaldizli, \u00d6, Maceski, A, et al.. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 2022;21:246\u201357. https:\/\/doi.org\/10.1016\/s1474-4422(22)00009-6.","DOI":"10.1016\/S1474-4422(22)00009-6"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_008","doi-asserted-by":"crossref","unstructured":"Abdelhak, A, Benkert, P, Schaedelin, S, Boscardin, WJ, Cordano, C, Oechtering, J, et al.. Neurofilament light chain elevation and disability progression in multiple sclerosis. JAMA Neurol 2023;80:1317\u201325. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3997.","DOI":"10.1001\/jamaneurol.2023.3997"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_009","doi-asserted-by":"crossref","unstructured":"Meier, S, Willemse, EAJ, Schaedelin, S, Oechtering, J, Lorscheider, J, Melie-Garcia, L, et al.. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol 2023;80:287\u201397. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5250.","DOI":"10.1001\/jamaneurol.2022.5250"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_010","doi-asserted-by":"crossref","unstructured":"Bittner, S, Oh, J, Havrdov\u00e1, EK, Tintor\u00e9, M, Zipp, F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain 2021;144:2954. https:\/\/doi.org\/10.1093\/brain\/awab241.","DOI":"10.1093\/brain\/awab241"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_011","doi-asserted-by":"crossref","unstructured":"Solberg, HE. Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. Clin Chim Acta 1987;170:S13\u201332. https:\/\/doi.org\/10.1016\/0009-8981(87)90151-3.","DOI":"10.1016\/0009-8981(87)90151-3"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_012","doi-asserted-by":"crossref","unstructured":"Ziemssen, T, Freedman, MS, Bar-Or, A, Montalban, X, Teunissen, CE, H\u00e4ring, DA, et al.. Clinical validation of a novel in\u00a0vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis. Mult Sclerosis 2025;31:1543\u201356. https:\/\/doi.org\/10.1177\/13524585251389797.","DOI":"10.1177\/13524585251389797"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_013","doi-asserted-by":"crossref","unstructured":"Ashrafzadeh-Kian, S, Figdore, D, Larson, B, Deters, R, Abou-Diwan, C, Bornhorst, J, et al.. Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays. Clin Chim Acta 2024;561:119817. https:\/\/doi.org\/10.1016\/j.cca.2024.119817.","DOI":"10.1016\/j.cca.2024.119817"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_014","doi-asserted-by":"crossref","unstructured":"Booth, RA, Beriault, D, Schneider, R, Benkert, P, Willemse, EAJ, Maceski, AM, et al.. Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay. Clin Chim Acta 2025;577:120447. https:\/\/doi.org\/10.1016\/j.cca.2025.120447.","DOI":"10.1016\/j.cca.2025.120447"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_015","doi-asserted-by":"crossref","unstructured":"Kuhle, J, Plavina, T, Barro, C, Disanto, G, Sangurdekar, D, Singh, CM, et al.. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. Mult Sclerosis 2020;26:1691\u20139. https:\/\/doi.org\/10.1177\/1352458519885613.","DOI":"10.1177\/1352458519885613"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_016","doi-asserted-by":"crossref","unstructured":"Kuhle, J, Kropshofer, H, Haering, DA, Kundu, U, Meinert, R, Barro, C, et al.. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 2019;92:e1007\u201315. https:\/\/doi.org\/10.1212\/wnl.0000000000007032.","DOI":"10.1212\/WNL.0000000000007032"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_017","doi-asserted-by":"crossref","unstructured":"Sejbaek, T, Nielsen, HH, Penner, N, Plavina, T, Mendoza, JP, Martin, NA, et al.. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment na\u00efve relapsing MS patients. J\u00a0Neurol Neurosurg Psychiatry 2019;90:1324\u201330. https:\/\/doi.org\/10.1136\/jnnp-2019-321321.","DOI":"10.1136\/jnnp-2019-321321"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_018","doi-asserted-by":"crossref","unstructured":"Cant\u00f3, E, Barro, C, Zhao, C, Caillier, SJ, Michalak, Z, Bove, R, et al.. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12\u00a0years. JAMA Neurol 2019;76:1359\u201366. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2137.","DOI":"10.1001\/jamaneurol.2019.2137"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_019","doi-asserted-by":"crossref","unstructured":"Barro, C, Benkert, P, Disanto, G, Tsagkas, C, Amann, M, Naegelin, Y, et al.. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 2018;141:2382\u201391. https:\/\/doi.org\/10.1093\/brain\/awy154.","DOI":"10.1093\/brain\/awy154"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_020","doi-asserted-by":"crossref","unstructured":"Rosso, M, Gonzalez, CT, Healy, BC, Saxena, S, Paul, A, Bjornevik, K, et al.. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. Ann Clin Transl Neurol 2020;7:945\u201355. https:\/\/doi.org\/10.1002\/acn3.51060.","DOI":"10.1002\/acn3.51060"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_021","doi-asserted-by":"crossref","unstructured":"Thebault, S, Reaume, M, Marrie, RA, Marriott, JJ, Furlan, R, Laroni, A, et al.. High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Mult Sclerosis Rel Disord 2022;59:103535. https:\/\/doi.org\/10.1016\/j.msard.2022.103535.","DOI":"10.1016\/j.msard.2022.103535"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_022","doi-asserted-by":"crossref","unstructured":"Kuhle, J, Nourbakhsh, B, Grant, D, Morant, S, Barro, C, Yaldizli, \u00d6, et al.. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 2017;88:826\u201331. https:\/\/doi.org\/10.1212\/wnl.0000000000003653.","DOI":"10.1212\/WNL.0000000000003653"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_023","doi-asserted-by":"crossref","unstructured":"Seiberl, M, Feige, J, Hilpold, P, Hitzl, W, Machegger, L, Buchmann, A, et al.. Serum neurofilament light chain as biomarker for cladribine-treated multiple sclerosis patients in a real-world setting. Int J Mol Sci 2023;24:4067. https:\/\/doi.org\/10.3390\/ijms24044067.","DOI":"10.3390\/ijms24044067"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_024","doi-asserted-by":"crossref","unstructured":"Barrero Hern\u00e1ndez, FJ, Romero Villarrubia, A, Mu\u00f1oz Fern\u00e1ndez, C, Guill\u00e9n Martinez, V, Aguilera Del Moral, A, Barrios-L\u00f3pez, JM, et al.. Real-world study of serum neurofilament light chain levels in ocrelizumab-treated people with relapsing multiple sclerosis. J\u00a0Pers Med 2024;14:692. https:\/\/doi.org\/10.3390\/jpm14070692.","DOI":"10.3390\/jpm14070692"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_025","doi-asserted-by":"crossref","unstructured":"Paolicelli, D, Ruggieri, M, Manni, A, Gargano, CD, Carleo, G, Palazzo, C, et al.. Real-life experience of the effects of cladribine tablets on lymphocyte subsets and serum neurofilament light chain levels in relapsing multiple sclerosis patients. Brain Sci 2022;12:1595. https:\/\/doi.org\/10.3390\/brainsci12121595.","DOI":"10.3390\/brainsci12121595"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_026","doi-asserted-by":"crossref","unstructured":"Benatar, M, Ostrow, LW, Lewcock, JW, Bennett, F, Shefner, J, Bowser, R, et al.. Biomarker qualification for neurofilament light chain in amyotrophic lateral sclerosis: theory and practice. Ann Neurol 2024;95:211\u20136. https:\/\/doi.org\/10.1002\/ana.26860.","DOI":"10.1002\/ana.26860"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_027","doi-asserted-by":"crossref","unstructured":"Adler, C, Onur, OA, Braumann, S, Gramespacher, H, Bittner, S, Falk, S, et al.. Absolute serum neurofilament light chain levels and its early kinetics predict brain injury after out-of-hospital cardiac arrest. J\u00a0Neurol 2022;269:1530\u20137. https:\/\/doi.org\/10.1007\/s00415-021-10722-3.","DOI":"10.1007\/s00415-021-10722-3"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_028","doi-asserted-by":"crossref","unstructured":"Mond\u00e9sert, E, Schraen-Maschke, S, Quadrio, I, Bousiges, O, Bouvier, D, Delaby, C, et al.. A French multicenter analytical evaluation of the automated lumipulse G sNfL blood assay (Fujirebio\u00ae) and its comparison to four other immunoassays for serum neurofilament light chain assessment in clinical settings. Clin Chim Acta 2025;565:120007. https:\/\/doi.org\/10.1016\/j.cca.2024.120007.","DOI":"10.1016\/j.cca.2024.120007"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_029","doi-asserted-by":"crossref","unstructured":"Shaw, G, Madorsky, I, Li, Y, Wang, Y, Jorgensen, M, Rana, S, et al.. Uman-type neurofilament light antibodies are effective reagents for the imaging of neurodegeneration. Brain Commun 2023;5:fcad067. https:\/\/doi.org\/10.1093\/braincomms\/fcad067.","DOI":"10.1093\/braincomms\/fcad067"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_030","doi-asserted-by":"crossref","unstructured":"Altmann, P, Leutmezer, F, Zach, H, Wurm, R, Stattmann, M, Ponleitner, M, et al.. Serum neurofilament light chain withstands delayed freezing and repeated thawing. Sci Rep 2020;10:19982. https:\/\/doi.org\/10.1038\/s41598-020-77098-8.","DOI":"10.1038\/s41598-020-77098-8"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_031","doi-asserted-by":"crossref","unstructured":"Arranz, J, Ferrer, R, Zhu, N, Rubio-Guerra, S, Rodr\u00edguez-Baz, \u00cd, Arriola-Infante, JE, et al.. Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer\u2019s disease in a tertiary memory clinic. Alzheimer\u2019s Res Ther 2025;17:150. https:\/\/doi.org\/10.1186\/s13195-025-01779-7.","DOI":"10.1186\/s13195-025-01779-7"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_032","doi-asserted-by":"crossref","unstructured":"Panikkar, D, Vivek, S, Crimmins, E, Faul, J, Langa, KM, Thyagarajan, B. Pre-analytical variables influencing stability of blood-based biomarkers of neuropathology. J\u00a0Alzheimer\u2019s Dis 2023;95:735\u201348. https:\/\/doi.org\/10.3233\/jad-230384.","DOI":"10.3233\/JAD-230384"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_033","doi-asserted-by":"crossref","unstructured":"van Lierop, ZYGJ, Verberk, IMW, van Uffelen, KWJ, Koel-Simmelink, MJA, In \u2019t Veld, L, Killestein, J, et al.. Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1. Clin Chem Lab Med 2022;60:842\u201350. https:\/\/doi.org\/10.1515\/cclm-2022-0007.","DOI":"10.1515\/cclm-2022-0007"},{"key":"2026051215045265922_j_cclm-2025-1476_ref_034","doi-asserted-by":"crossref","unstructured":"Verberk, IMW, Misdorp, EO, Koelewijn, J, Ball, AJ, Blennow, K, Dage, JL, et al.. Stability of the novel blood-based biomarkers under pre-analytical sample handling conditions: results of the SABB-GBSC working group. Alzheimer\u2019s Dementia 2021;17:e055441. https:\/\/doi.org\/10.1002\/alz.055441.","DOI":"10.1002\/alz.055441"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1476\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1476\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:09:23Z","timestamp":1778598563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1476\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,26]]},"published-print":{"date-parts":[[2026,3,26]]}},"alternative-id":["10.1515\/cclm-2025-1476"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-1476","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}